Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Raza, Syed SKhan, Hala
Hajibandeh, Shahab
Hajibandeh, Shahin
Bartlett, David
Chatzizacharias, Nikolaos
Roberts, Keith
Marudanayagam, Ravi
Sutcliffe, Robert P
Publication date
2024-02-01
Metadata
Show full item recordAbstract
Background: To investigate the relationship between preoperative Carbohydrate Antigen19-9(CA19-9)and pancreatic cancer occult metastasis. Methods: Systematic search of MEDLINE, CENTRAL, Web of Science and bibliographic reference lists were conducted. All comparative observational studies investigating the predictive ability of preoperative CA 19-9 in patients with pancreatic cancer were considered. Mean CA-19-9 value in the pancreatic cancer patients with and without metastasis were evaluated. Best cut-off value of CA 19-9 for metastasis was determined using ROC analysis. Results: Ten comparative observational studies reporting a total of 1431 pancreatic cancer patients with (n = 496) and without (n = 935) metastasis were included. Subsequent meta-analysis demonstrated that mean preoperative CA 19-9 level was significantly higher in patients with metastases compared to those without (MD: 904.4; 95 % CI, 642.08-1166.74, P < 0.0001). The between-study heterogeneity was significant (I2: 99 %, P < 0.00001). ROC analysis yielded a cut-off CA 19-9 level of 336 with a sensitivity and specificity for predicting metastasis of 90 % and 80 %, respectively (AUC = 0.90). Conclusions: CA 19-9 level is significantly higher in patients with metastatic pancreatic cancer. A preoperative CA 19-9 value of 336 should be considered as an acceptable cut-off value to design prospective studies.Citation
Raza SS, Khan H, Hajibandeh S, Hajibandeh S, Bartlett D, Chatzizacharias N, Roberts K, Marudanayagam R, Sutcliffe RP. Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis. HPB (Oxford). 2024 May;26(5):630-638. doi: 10.1016/j.hpb.2024.01.017. Epub 2024 Feb 1.Type
ArticleAdditional Links
http://www.sciencedirect.com/science/journal/1365182Xhttps://onlinelibrary.wiley.com/journal/14772574?journalRedirectCheck=true
PMID
38383207Journal
HPBPublisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.hpb.2024.01.017